PHAXIAM Therapeutics S.A. (PHXM) - Total Liabilities

Latest as of June 2024: €23.66 Million EUR ≈ $27.66 Million USD

Based on the latest financial reports, PHAXIAM Therapeutics S.A. (PHXM) has total liabilities worth €23.66 Million EUR (≈ $27.66 Million USD) as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PHXM operating cash flow to assess how effectively this company generates cash.

PHAXIAM Therapeutics S.A. - Total Liabilities Trend (2010–2023)

This chart illustrates how PHAXIAM Therapeutics S.A.'s total liabilities have evolved over time, based on quarterly financial data. Check PHAXIAM Therapeutics S.A. asset resilience ratio to evaluate the company's liquid asset resilience ratio.

PHAXIAM Therapeutics S.A. Competitors by Total Liabilities

The table below lists competitors of PHAXIAM Therapeutics S.A. ranked by their total liabilities.

Company	Country	Total Liabilities
AfriTin Mining Ltd LSE:ATM	UK	GBX43.56 Million
Edri-El TA:EDRL	Israel	ILA53.33 Million
Troubadour Resources Inc V:TR	Canada	CA$325.75K
Brave Bison Group PLC LSE:BBSN	UK	GBX14.90 Million
Mastrad PA:ALMAS	France	€3.00 Million
BioNeutra Global Corp V:BGA	Canada	CA$21.81 Million
Ten Lifestyle Group PLC LSE:TENG	UK	GBX28.15 Million
Satis Group S.A. WAR:STS	Poland	zł274.74 Million

Liability Composition Analysis (2010–2023)

This chart breaks down PHAXIAM Therapeutics S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PHAXIAM Therapeutics S.A. market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.38	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	0.09	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.53	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.60	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how PHAXIAM Therapeutics S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for PHAXIAM Therapeutics S.A. (2010–2023)

The table below shows the annual total liabilities of PHAXIAM Therapeutics S.A. from 2010 to 2023.

Year	Total Liabilities	Change
2023-12-31	€25.70 Million ≈ $30.04 Million	+15.10%
2022-12-31	€22.32 Million ≈ $26.10 Million	-49.17%
2021-12-31	€43.92 Million ≈ $51.35 Million	-18.45%
2020-12-31	€53.86 Million ≈ $62.97 Million	+63.29%
2019-12-31	€32.99 Million ≈ $38.56 Million	+48.33%
2018-12-31	€22.24 Million ≈ $26.00 Million	+60.66%
2017-12-31	€13.84 Million ≈ $16.18 Million	+48.38%
2016-12-31	€9.33 Million ≈ $10.91 Million	+58.87%
2015-12-31	€5.87 Million ≈ $6.86 Million	+22.79%
2014-12-31	€4.78 Million ≈ $5.59 Million	+9.63%
2013-12-31	€4.36 Million ≈ $5.10 Million	-69.22%
2012-12-31	€14.17 Million ≈ $16.57 Million	+106.96%
2011-12-31	€6.85 Million ≈ $8.00 Million	+165.59%
2010-12-31	€2.58 Million ≈ $3.01 Million	--

About PHAXIAM Therapeutics S.A.

PA:PHXM France Biotechnology

Market Cap

$1.18 Million

€1.01 Million EUR

Market Cap Rank

#30193 Global

#572 in France

Share Price

€0.10

Change (1 day)

+0.00%

52-Week Range

€0.10 - €0.41

All Time High

€283.83